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Abstract
Background: Even though the WHO currently recommends zinc for diarrhea management, no consensus has been
reached with respect to routine distribution of zinc for preventive reasons. We reviewed the health impact of
preventive zinc interventions, and evaluated the relative cost effectiveness of currently feasible interventions.
Methods: Using the latest relative risk estimates reported in the literature, we parameterized a health impact model,
and calculated the expected benefits of zinc supplementation in a representative low-income country. We then
computed the cost and cost-effectiveness for three delivery mechanisms: the direct distribution of zinc supplements,
the distribution of micronutrient biscuits including zinc, and the distribution of zinc through water filtration systems.
Results: Combining all health outcomes and impact estimates, we find that systematic zinc supplementation among
children of ages one to five would avert 1.423 DALYs per 100 households and year in least developed countries. The
estimated cost per DALY is US$ 606 for pill supplementation, US$ 1211 for micronutrient biscuits, and US$ 879 per
DALY saved for water filtration systems.
Conclusions: Preventive zinc supplementation to children of ages 1–5 appears to be a highly cost-effective
intervention in typical developing country settings. More research will be needed to determine the most effective
mechanism to deliver zinc to this target population.
Keywords: Zinc supplementation, Cost-effectiveness, Diarrhea, ALRI
Background
Zinc affects the human body through a large number of
channels affecting not only cell division, protein synthesis
and growth, but also gene expression and a variety of re-
productive and immunologic functions [1]. The absence
of sufficient levels of zinc in the human body is associated
with a large number of adverse health outcomes, including
reduced physical growth, lower immune competence and
suppressed neural development [2]. The global burden of
disease due to zinc deficiency is estimated at 800,000
excess deaths among children under 5 years of age annually,
most of which are attributed to pneumonia, diarrhea and
malaria [3]. Even though the World Health Organization
(WHO) recommends zinc for diarrhea management [4,5],
no consensus has been reached with respect to routine
distribution of zinc for preventive reasons.
A large and rapidly growing literature has explored
the degree to which zinc supplementation can improve
population health in general, and child health in particular
[6-10]. While some studies have documented negative
effects of zinc supplementation on iron absorption [11], the
adverse effects of zinc supplementation on concentrations
of hemoglobin, serum ferritin, and serum copper appear
limited [12-15]. Given this, the case for more compre-
hensive zinc supplementation programs seems promising,
and naturally raises the question regarding the potential
delivery mechanisms for zinc and their relative cost
effectiveness.
While direct dietary supplementation is the most
commonly used approach in trials, several other delivery
mechanisms have been proposed in the literature: Hess
and Brown [16] highlight the potentially large benefits
of food fortification with zinc oxide or zinc sulfate; Gibson
and Anderson [17] review the potential benefits of dietary
diversification, and Hotz [7] makes a case for a more
general biofortification of staple crops in developing
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both zinc supplementation and zinc fortification as
potentially cost-effective interventions [18], a general
delivery of zinc through centrally produced wheat or
other staple foods may be difficult in many developing
countries today due the small scale and decentralized
structure of most agricultural sectors in developing
countries, and because fortification programs may miss
rural populations and those urban poor who consume
few processed foods [19]. While bio-fortification appears
to be an attractive and culturally appropriate alternative in
principal [19,20], the upfront cost of genetically modified
crop development appears high [19], so that implementa-
tion at a meaningful scale is highly unlikely to happen in
the near future. In this paper, we focus on mechanisms to
implement large scale zinc supplementation which appear
feasible in the near term, compute their relative cost-
effectiveness and discuss both the feasibility and scalabil-
ity of each mechanism.
Methods
In order to assess the cost-effectiveness of zinc supplemen-
tation under the various distribution scenarios, we pro-
ceeded in four steps. In a first step, a systematic literature
review was conducted using both the Google Scholar and
PubMed search engines. Given the large number of review
studies in the area, the literature review was restricted to
meta-studies based on randomized controlled trials with
a focus on preventive zinc supplementation. All review
studies meeting these criteria were independently evalu-
ated by both authors. Mismatching coding was reconciled
by a joint review of the relevant papers.
In a second step, the meta-studies were used to
parameterize a health impact model to calculate the
expected benefits of zinc supplementation in an aver-
age low-income country. The model was based on the
standard cost-effectiveness procedures outlined by the
Panel on Cost Effectiveness in Health and Medicine
[21], taking the perspective of an external financing
agency. Following WHO guidelines [22], health bene-
fits were calculated in terms of disability adjusted life
years (DALYs) saved through one year of supplementation
for groups of 100 households. Following Stein [19], DALYs
were computed using the following equation:
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X
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where Tj is the number of people in target group j, Mj
is the mortality rate associated with the condition in tar-
get group j,Lij is the average remaining life expectancy
for target group j, Iij is the incidence rate of health out-
come i in group jDis the corresponding disability
weight, d is the duration of the health outcome, and r is
the temporal discount rate, which we assume to be 3%
as recommended [22]. Disability weights for both were
taken from standard Global Burden of Disease Database
(GBD) [23]. Morbidity effects were assumed to be mutually
exclusive, so that each case of child morbidity was either
classified as diarrhea, malaria or acute lower respiratory
illness (ALRI) only. Mortality effects were modeled as po-
tential outcome (consequence) of child morbidity.
In order to calibrate the model to a representative
developing country setting, data on average household
characteristics in countries classified as least developed
were extracted from the United Nations World Popula-
tion Prospects data base [24]. Seventy-seven countries
were classified as “least developed”, with a total population
of about 900 Million people across 3 continents. Incidence
data for both diarrhea and ALRI in developing countries
was derived from representative household surveys data
collected through the Demographic and Health Surveys
(DHS) [25]. These surveys contain two-week-disease-spe-
cific prevalence data, which were converted to annual
incidence numbers. Baseline data on child mortality was
downloaded from UNICEF’sS t a t eo fT h eW o r l d ’sC h i l -
dren database [26]. Applying Equation 1 to the data from
UNICEF, the GBD, and the DHS surveys, number of
DALYs currently being lost for a synthetic set of 100
households in “least developed” countries was calculated.
In a third step, we analyzed the relative effectiveness of
three potential delivery mechanisms for zinc. The most
commonly studied delivery mechanism for zinc supple-
mentation in clinical trials is direct distribution of zinc
pills [27-29]. An alternative approach to zinc supplemen-
tation is the distribution of micronutrient biscuits; such
biscuits (or sprinkles for cereals) have been shown to be
highly effective in reducing anemia and increasing plasma
zinc among school children [30]. The third delivery mecha-
nisms considered was the deployment of home-based water
filtration systems. Such systems are currently in the trial
stage, and designed to directly dispense zinc into drinking
water as part of the water filtration process.
Relative risks of diarrhea and ALRI for interventions
supplying zinc were taken from published literature on
zinc supplementation and applied to current incidence
rates for these diseases in the synthetic set of 100 repre-
sentative households. Using these new incidence rates,
the DALYs that would still be lost amongst the synthetic
households was calculated, and the difference from the
DALYs in step two was taken as the incremental reduction
in DALYs from providing these interventions to the 100
synthetic households.
In the fourth step, cost estimates for each of the
delivery mechanisms analyzed were compiled from recently
published trials as well as other online resources. For all
interventions, the most recent cost estimates were taken.
Given that no evidence was found suggesting an increase
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flation adjustments were made. Dividing the estimated
cost of delivery by the incremental reduction in DALYS
from providing each intervention yielded the incremental
cost effectiveness of providing each intervention to 100
synthetic households given current disease trends. For all
cost-effectiveness calculations the assumed counterfactual
was no intervention at all, i.e. that none of the other inter-
ventions considered would be implemented, which means
that incremental cost-effectiveness estimates equal mean
cost-effectiveness estimates.
All data utilized in the analysis came from existing
sources, and no human subjects research was performed.
Results
Literature review
The literature search revealed a remarkably large number
of studies investigating the effects of zinc. More than two
million studies contained zinc as keywords in Google
Scholar, and more than 20,000 studies were linked to zinc
supplementation, prevention and mortality in the same
search engine. From the 199 meta or review studies found
in Google Scholar, 186 were unrelated to morbidity or
mortality prevention or were merely citations, corrections,
posters, or used otherwise inappropriate formats, 4 were
unrelated to dietary intake in humans, and 3 contained gen-
eral discussions rather than empirical evidence. This left six
articles from the Google Scholar search which contained
meta analyses of the relationship between zinc supplemen-
tation and mortality or morbidity prevention. A second
search on meta-studies related to zinc was conducted in
PubMed. Based on the keyword “zinc” and limited to meta-
analysis, 103 studies focusing on human subjects were iden-
tified. 35 were excluded because they were not related to
zinc supplementation; 25 were related to treatment rather
than to prevention, 14 measured risk factors (such as height
or weight or chemical concentrations) rather than health
outcomes, 5 studies were not based on clinical trials; and
one study was excluded due to the lack of a comparable
placebo group. Six studies were older versions of updated
articles already included and thus also omitted, which
resulted in a final selection of 17 meta-analysis from the
PubMed search, four of which were also found in the Goo-
gle Scholar search. Finally, two articles were included from
other previously known sources and searches. This made a
total of 21 studies selected for the final review.
Health impact of zinc supplementation
Diarrheal diseases
Aggarwal et al. [31] reviewed all controlled trials on
diarrheal outcomes published up to November 2005.
The pooled analysis yielded a statistically significant
relative risk (RR) for mild or severe diarrhea of 0.86, with
a 95% confidence interval of [0.79-0.95]. The RR for severe
diarrhea was 0.85 [0.75-0.95], and 0.75 [0.57-0.98] when
looking at persistent diarrhea. Brown et al. [13] included
87 articles published before May 2007. The pooled ana-
lysis found a significant protective effect: RR=0.80, 95%
CI [0.71-0.90]. No effects were found in studies with mean
age of children 12 months or younger. The effect was lar-
gest for children 12 months or older RR=0.73, 95% CI
[0.61 – 0.87]. Yakoob et al. [9] reviewed 14 studies quali-
fied as “high quality”, and found a pooled risk reduction of
13% (RR=0.87; 95% CI [0.81, 0.94]). Patel et al. [32] con-
ducted the most comprehensive review of the literature
on diarrheal diseases to date, reviewing all studies up to
2011 including three preceding meta-studies. The pooled
analysis yielded a summary rate ratio of 0.91 [0.87-0.95].
The estimated prevalence effect was larger, with a risk
ratio of 0.81 [0.75-0.88]. When adjusting for cluster
randomization, the estimated range was [0.88-0.94].
Respiratory infections
Aggarwal et al. [31] reviewed 12 studies investigating the
effect of zinc supplementation on respiratory illness. The
summary relative risk was 0.92 [0.85-0.99]. Four reviewed
studies investigated acute lower respiratory infection
(ALRI), with a pooled RR of 0.80 [0.70-0.92]. Brown
et al. [8] reviewed 16 comparisons based on 12 studies
on ALRI, and found a pooled relative ALRI risk of 0.85
[0.75-0.97]. With a stringent definition (physician exam or
counting respiratory rates, 9 comparison groups) a relative
risk of 0.79 [0.67-0.94] was found. Roth et al. [28] updated
the previous reviews with a particular focus on ALRI. A
total of 10 studies were included. Using the least specific
definition provided to address differences in ALRI diagno-
sis, the pooled estimate was an insignificant rate ratio of
0.94 [0.88-1.01]. Using the most specific definition pro-
vided by each paper, the pooled estimate was an insignifi-
cant protective rate ratio of 0.86 [0.74-1.01]. Lassi et al.
[33] review six trials on pneumonia, and find an average
risk reduction of 13% (RR=0.87, 95% CI [0.81,0.94]).
Yakoob et al. [9] re-analyzed existing randomized con-
trolled trials in the areas and found a morbidity reduction
of 19% (RR=0.81; 95% CI [0.73, 0.90]).
Zinc and under-5 mortality
Brown et al. [13] found a relative risk of death of 0.94
[0.86-1.02]. In larger trials zinc supplementation reduced
mortality of children 12 months old or older by 18%
(RR= 0.82, 95% CI [0.70–0.96]), but had no effect on
younger children. Yakoob et al. [9] found that Zinc
supplementation alone was associated with a 9% reduc-
tion in all-cause mortality risk (RR=0.91; 95% CI [0.82,
1.01]), but no effect in studies that also supplemented iron
and folic acid. The point estimates were larger for mortal-
ity attributable to malaria and diarrhea, but not statisti-
cally significant.
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Based on the literature search results, the protective effect
of zinc appeared relatively robust for diarrheal diseases,
respiratory infections and all-cause mortality. There ap-
pears to be also growing evidence on a protective effect of
zinc on malaria, while the evidence on diabetes, HIV and
other diseases appears limited, so that the protective effect
on these outcomes was assumed to be zero. While few
studies focus on sub-group analysis, all reviewed studies
suggested a noticeable heterogeneity in study outcomes
related to diarrhea incidence. Study populations or
subgroup analyses wherein the average child is stunted
saw the largest protective effects of zinc interventions
[8,27,34-37]. Conversely, studies or subgroups with an
average length-for-age or height-for-age Z-score above
−1.5 tended to see insignificant effects [37-44]. While
there are two noteworthy exceptions to these patterns
[45,46] it appears plausible that zinc supplementation
would primarily work among children with nutritional
deficits. Zinc is known to inhibit growth, and stunting
is widely considered the best anthropometric indicator of
risk of zinc deficiency [47]. The proposition of increased
morbidity protection amongst stunted children is analo-
gous to the documented evidence that zinc supplementa-
tion elicits stronger growth responses amongst stunted
children over 6 months of age [48]. In addition to baseline
nutrition, age seems to be an important modifier of the
health benefits generated by zinc, with children over
12 months of age benefitting more than infants where
benefits appear limited [49].
For several of the parameters, point estimates varied
considerably across studies. To capture this, three different
scenarios were considered: a baseline scenario, an opti-
mistic scenario, and a pessimistic scenario. The baseline
estimates were chosen with the following decision rule:
For each age/height-for-age/disease subgroup in our
model, we chose the point estimate of the meta-analysis
that most demographically matched our desired subgroup.
If two meta-analyses covered the same demographic com-
position, we chose estimate from the more comprehensive
meta-analysis. The “optimistic” scenario captures the
highest effect reported in recent studies; the “pessimistic”
scenario captures the lowest meta-estimate found in the
reviews.
Health effect parameters were modeled to be equal across
zinc delivery modes. Virtually all existing evidence on
the health effects of preventive zinc are based on zinc
supplementation trials, and we assume that the health
benefits documented for supplementation trials can be
achieved by all other delivery modes considered. This
m i g h tn o tb et h ec a s ei fz i n ci sd i f f e r e n t i a l l ya b s o r b e d
across modes. In practice, absorption may be difficult
in the presence of phytate, which is a known inhibitor
of zinc absorption found in grains [50]. Iron can also
act as an inhibitor of zinc absorption, though in lower
doses [51] or when incorporated into meals [50-52] this
effect is greatly dampened. More generally, the potentially
deleterious interactions between simultaneous zinc and
iron delivery should be carefully considered when delivery
modes are developed [53-56].
Evidence for other modes is very limited A recent
meta-analysis on micronutrient powders (MNP) including
zinc neither finds no effect of MNP on zinc deficiency nor
or child health [57]. A recent systematic review on food
(formula, milk or porridge) fortification interventions sug-
gests a positive impact of these interventions on serum
zinc concentration, positive weight gains for zinc-deficient
school age children, and positive height gains for infants
with very low birth weight, but also highlights the “[.]
dearth of evidence for the impact of fortification strategies
on morbidity and mortality outcomes in women and
children” [58]. For aqueously dissolved zinc, high rates of
absorption seem feasible. Tran et al. [59] found that the
fractional absorption of zinc ranged from 0.62 to 0.73 for
aqueous zinc sulfate doses of 2 mg to 15 mg, with declining
fractional absorption for 20 and 30 mg dosing. Solomons
et al. [60] compare the absorption of aqueous zinc sulfate
with the absorption of NutriSet tablets, and find that aque-
ous zinc administration doubles the bioavailability of zinc
compared to the NutriSet tabs. To date, no evidence on the
health impact of aqueous zinc is available.
In addition to the lacking evidence for the health ben-
efits for delivery modes other than direct supplementa-
tion, evidence is also very scarce on the health benefits
of supplemental zinc for children over 5, not allowing
any general conclusions. Given this, the health benefits
were assumed to be zero over the age of 5 under all sce-
narios. Table 1 shows the full set of parameter choices
made under each scenario, separately for infants (age 0–
11 months) and children (ages 12–59 months), and by
stunting classification.
Household structure and baseline burden of diseases
Table 2 shows the assumptions made regarding house-
hold structure and haseline burden of disease. Average
household size in the pooled least developed country
group was assumed to be five in line with Bongaarts’ es-
timates [61]. Based on the World Population prospect
data, each 100 households were assumed to host 15 in-
fants, 59 children of ages 1–5, 127 5–14 year olds, and
299 individuals of age 15 or older [24]. Annual morbidity
incidence was estimated at 3.42 cases of diarrhea, and
2.51 cases of ALRI per child and year using the DHS
data [25]. Under-five mortality was estimated at 63 deaths
per thousand live births in 2010, out of which 44 deaths
occur in the first year of life. Assuming a uniform mor-
tality distribution between ages 1 and 5 for simplicity,
this converted to an annual mortality rate of 4.75 deaths
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dren were estimated as being stunted [62]. Using Black’s
estimates [63], mortality rates were allocated into mortal-
ity among stunted and non-stunted children, with 60 per-
cent higher mortality odds in the stunting group.
Delivery cost
Several studies reviewed reported the cost for thera-
peutic treatments with zinc, which were used to estimate
supplementation costs. While treatment doses are gen-
erally higher for therapeutic purposes than for supplemen-
tation (20 mg/day vs. 10 mg/day for supplementation), the
average wholesale price is unlikely to differ much. Abdullah
Brooks [64], Robberstad [29], and Srinivasan [65] suggest a
price per 20 mg pill of between 2 – 6 cents, while Gitanjali
[66] reports that a two week course can cost the Tamil
Nadu government less than two rupees, equivalent to under
a third of a penny per pill. We take the midpoint of 2–6
and assume 4 cents per pill in our baseline scenario, and
use 6 cents (the highest estimate) and 1 cent (near the
Gitanjali estimate) as pessimistic and optimistic scenarios
(Table 3).
As to the distribution cost of micro-nutrients, the
current estimate is about $ 0.08 per child and day [30],
which we use both for our baseline and pessimistic calcu-
lation. Similar doses of zinc sulfate could also be added to
children’s food through micronutrient powder or “sprin-
kles”, with an estimated cost of $ 0.03 or less according to
the World Food Programme [67]. We take $0.03 as the op-
timistic scenario for micronutrient distribution.
The supplementation costs above were calculated as
the cost to provide one treatment to one person on one
day. Multiplying by 365 the daily costs in Table 3 and
further multiplying by the number of treated children in
100 synthetic households from Table 1 yielded the total
annual costs of these interventions. It is noteworthy that
only Robberstad et al. [29] explicitly cost all the individual
components of treatment delivery in the private market
and aggregate them into a total. Gitanjali & Weerasuriya
Table 1 Health impact summary for infants and children of age 1–5, by stunting status
Baseline Optimistic scenario Pessimistic scenario
Health impact for stunted children ages 1-5
Risk reduction: Diarrhea 0.87 Yakoob [9] 0.73 Brown [13] 0.91 Patel [32]
Risk reduction: ALRI 0.86 Roth [28] 0.81 Yakoob [9] 0.94 Roth [28]
Risk reduction: Child mortality 0.82 Brown [13] 0.82 Brown [13] 0.94 Brown [13]
Health impact for non-stunted children ages 1-5
Risk reduction: Diarrhea 1 Brown [13] 0.73 Brown [13] 1 Brown [13]
Risk reduction: ALRI 0.86 Roth [23] 0.81 Yakoob [27] 1 Lower limit
Risk reduction: Child mortality 0.82 Brown [8] 0.82 Brown [8] 0.94 Brown [8]
Health impact for stunted infants
(Age 0–11 months)
Risk reduction: Diarrhea 1 Brown [13]&G u l a n i[ 6] 1 Brown [13] 1 Brown [13] & Gulani [6])
Risk reduction: ALRI 1 Gulani [6] 0.81 Yakoob [9] 1 Lower limit
Risk reduction: Child mortality 1 Brown [13] 0.91 Yakoob & Brown [9,13] 1 Brown [13]
Health impact for non-stunted infants
(Age 0–11 months)
Risk reduction: Diarrhea 1 Brown [13]&G u l a n i[ 6] 1 Brown [13] 1 Brown [13] & Gulani [6]
Risk reduction: ALRI 1 Gulani [6] 0.81 Yakoob [9] 1 Lower limit
Risk reduction: Child mortality 1 Brown [13] 0.91 Yakoob [9] & Brown [13] 1 Brown [13]
Table 2 Population and baseline health parameters
Household structure Source
Infant per 100 households 14.7 UN [24]
Children age 1–4 per 100 households: all 58.9 UN [24]
Children age 1–4 : stunted 18.8 UN [24], Black [63]
Children age 1–4: not stunted 40.1 UN [24], Black [63]
Children age 5–14 per 100 households 127.0 UN [24]
Persons ages 15 and older per 100
households
299.4 UN [24]
Baseline burden of disease
Diarrhea 3.42 DHS [25]
ALRI 2.51 DHS [25]
Infant mortality: deaths per 1000 44 UNICEF [26]
Child mortality all: deaths per 1000 19 UNICEF [26]
Annual child mortality: stunted 6.4 UNICEF [26], Black [63],
author’s calculations
Annual child mortality: not-stunted 4.0 UNICEF [26], Black [63],
author’s calculations
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refer only to the price of zinc. The other estimates simply
report per-treatment “cost” without specifying which
components of the intervention are being considered.
Water filtration systems are currently under develop-
ment, and would, according to the latest cost estimates
provided by Vestergaard Frandsen cost about US$ 25–35
per year. This reflects an additional cost of about US$ 5
compared to standard water filtration systems for the zinc
dispensing feature (optimistic US$ 2, pessimistic US$ 10).
Table 3 provides a summary of the cost assumptions made
for the cost effectiveness calculations.
Cost effectiveness results
Combining all health outcomes and impact estimates,
systematic zinc supplementation among children under
the age of five was estimated to annually avert 1.4. DALYs
per 100 households in least developed countries. Using
the most pessimistic and most optimistic health impact
scenarios as upper and lower bounds for this estimate, a
range of 0.5 - 3.1 DALYs per 100 households and year was
found. Given that both the cost and impact estimates var-
ied substantially, separate cost-effectiveness calculations
were conducted under more or less optimistic cost and
health impact scenarios. In Table 4, the main health im-
pact estimate of 1.4 DALYs per 100 households was used
in combination with a range of cost estimates. Column 1
shows the results for the distribution of zinc supplements
to children under five. With an estimated baseline cost of
4 cents per pill and day (US$ 14.6 per year and child), the
estimated cost per DALY is US$ 606; depending on the
cost assumptions made, this number fluctuated between
US$ 151 and US$ 908.
Column 2 of Table 4 shows the results for micronutrient
biscuits or the addition of micronutrient powder. Given
the higher price per dose, the overall cost-effectiveness es-
timates looked slightly less favorable, with a main estimate
of US$ 1211 per DALY, and optimistic and pessimistic
bounds of US$ 454 and US$ 1211, respectively. Columns
3 and 4 of Table 5 show the results for water filter based
systems. The cost structure of water filtration systems is
fairly different from the distribution of supplements or
biscuits, with the bulk of the attributable to manufacturing
and only minor costs accruing once the filters are in-
stalled. Water filtration systems were assumed to last for
two years on average, which translates to a cost of US$
12.5 per household. With an average of 59 children in the
critical age bracket, this translates to a cost of US$ 879
per DALY saved. Depending on the actual price of the
water filtration system, this cost-effectiveness estimate
ranges between US$ 527 and US$ 1230. When only the
additional cost of adding zinc dispensing function to the
water filtration systems was taken into account, the cost-
effectiveness numbers looked substantially more favorable,
ranging between US$ 70 and US$ 351 with a baseline esti-
mate of US$ 175. In order to highlight the sensitivity of
these estimates with respect to the underlying health im-
pact, separate cost-effectiveness numbers were calculated
for the four delivery mechanisms under the optimistic and
pessimistic case health scenarios. The results of this sensi-
tivity analysis are displayed in Table 5. On average, the
cost per DALY drops to about 45% under the most opti-
mistic health impact scenario, while it increases by about
200% if the most conservative health impact estimates are
applied. Figure 1 summarizes the overall sensitivity of the
results with respect to efficacy and cost.
Table 3 Estimated cost by delivery mechanisms
Cost of zinc supplementation Base case Optimistic bound Pessimistic bound
Prophylactic supplements per dose 0.04 0.01 0.06 Brooks [64]
Annual per-person cost 14.60 3.65 21.90 Robberstad [29],
Srinivasan [65],
Gitanjali [66]
Micronutrient biscuits or sprinkles 0.08 0.03 0.08 Nga et al. [30],
Annual per-person cost 29.20 10.95 29.20 WFP
Water filter system per household 25 15 35 Vestergaard Frandsen
Water filter: zinc supplementation only per household 5 2 10 Vestergaard Frandsen
Table 4 Incremental cost-effectiveness under the main health scenario
Scenario Cost per DALY: Prophylactic
supplements for children 1–4 only
Cost per DALY:
Biscuits
Cost per DALY
Water filter systems
Cost per DALY water
filter zinc addition only
Baseline cost 605.50 1211.00 878.66 175.73
Optimistic cost 151.38 454.13 527.20 70.29
Pessimistic cost 908.25 1211.00 1230.12 351.46
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The results of this paper suggest that several inter-
ventions to address zinc deficiency are likely to be
cost-effective under standard cost-effectiveness as-
sumptions. For all delivery mechanisms analyzed, our
preferred model specification suggests average costs
per DALY strictly below US$ 1500, which implies that
all interventions should be considered highly cost-
effective in most countries currently classified as least
developed countries under the WHO cost-effectiveness
guidelines [22].
Several modeling assumptions limit the generalizability
of the results, and are worth highlighting. First, all of
our the cost-effectiveness calculations are based on the
evidence from trials administering zinc in the form of
tablets or syrup. Zinc absorption and the resulting health
impact may differ across delivery modes, which would
clearly affect the cost-effectiveness results presented in
this paper. Second, while a large number of studies have
analyzed the health benefits of zinc for children under 5,
very little evidence is available for older children and
adults. In the absence of better evidence, we assumed the
Table 5 Sensitivity analysis: health impact scenarios
Health impact: Optimistic
Cost per DALY: Prophylactic
supplements for children 1–4 only
Cost per DALY:
biscuits
Cost per DALY
water filter systems
Cost per DALY water
filter zinc addition only
Baseline cost 260.68 521.36 378.28 75.66
Optimistic cost 65.17 195.51 226.97 30.26
Pessimistic cost 391.02 521.36 529.59 151.31
Health impact: Pessimistic
Cost per DALY: Prophylactic
supplements for children 1–4 only
Cost per DALY:
biscuits
Cost per DALY
water filter systems
Cost per DALY water
filter zinc addition only
Baseline cost 1838.45 3676.90 2667.82 533.56
Optimistic cost 459.61 1378.84 1600.69 213.43
Pessimistic cost 2757.67 3676.90 3734.95 1067.13
Figure 1 Sensitivity analysis. a: Tornado Chart for Supplementation and Biscuits. b: Tornado Chart for Water System and Water Filter.
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(rather likely) case that older populations also benefit from
supplementation, the cost-effectiveness numbers reported
here would clearly underestimate the true effectiveness
of zinc interventions in general, and of water filtration
systems in particular, where older household members
are naturally exposed to zinc due to the household-based
nature of the intervention. Third our model is calibrated
to a representative household in a developing country. To
the extent that a specific country has higher dependency
ratios or higher rates of stunting, the average numbers
used in this analysis will be an underestimate of the health
impact achievable and the actual cost-effectivenessof the
respective programs. We also assumed that adherence to
each treatment was perfect, which is unlikely to hold in
general, and with pill supplementation in particular.
While both zinc supplementation through pills and multi-
nutrient biscuits have been successfully implemented in
controlled trials, limited evidence is available to date re-
garding the scalability and adherence to such interven-
tions over time. Last, we only considered technologies
currently available; new technologies to deliver zinc such
as genetically modified crops are likely to improve the
cost-effectiveness numbers substantially.
A potential shortcoming of our paper is that some evi-
dence suggests our model may underestimate its efficacy.
There is suggestive evidence that zinc supplementation
can potentially reduce the burden of several other illnesses,
including malaria, HIV, diabetes, depression. However,
we found the empirical evidence too limited to include
these impacts in the present study. For relevant discus-
sions, see Yakoob et al. [9] Brown et al. [13], Zeng and
Zhang [10], Sigfried [68], Humphreys [69], Islam and
Loots [70],. Lai et al. [71], Nagala et al. [72], Kulier et al.
[73], and Worthington et al. [74].
Overall, the health benefits achievable through systematic
zinc supplementation appear large, while several important
questions remain open with respect to its feasibility. Even if
existing health system resources such as community health
worker programs could be used to distribute zinc supple-
ments on a regular basis, comprehensive zinc coverage
through the distribution of zinc supplements would be a
major challenge, and assuring adherence to treatment
over time would undoubtedly be difficult. From a purely
coverage-focused perspective, genetically modified crops
would clearly be the first best option, since they would
allow eliminating zinc deficiencies without requiring
major behavioral changes from children and their par-
ents. In the absence of such crops, which would likely
take several years before being adopted by the agricultural
sector even once developed, home-based water filtration
systems could become an interesting alternative. Home
based water filtration have been shown to be highly effect-
ive in reducing diarrhea [75] and thus constitute an
effective intervention themselves in many developing
country settings where water contamination at the point
of use is common [75,76]. At a price of US$ 20–30, these
filters are likely to be highly cost-effective, but also likely
too expensive to be currently affordable for the average
household in low income countries [77]. To the extent
that governments or international agencies are willing to
support the mass distribution of household water filtration
systems, moving towards filters with additional zinc fea-
tures may become an interesting alternative. However, fur-
ther field trials will be needed to assess the reliability of
such systems as well as zinc absorption rates among indi-
viduals heterogeneous in their age, water consumption
and zinc needs.
Conclusions
The results presented in this paper suggest that preventive
zinc supplementation to children of ages 1–4s h o u l db e
considered a highly cost-effective intervention. Several
delivery mechanisms promise to be cost-effective in
principal. However, further research will be needed to
establish the feasibility and impact of each mechanism
at larger scale.
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